| Induction chemotherapy before sleeve lobectomy for lung cancer: immediate and long-term results. | |
| | |
MedLine Citation:
|
PMID: 19932225 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Induction chemotherapy does not increase the morbidity and mortality rates of bronchoplastic procedures, but the long-term efficiency remains unclear. The purpose of this retrospective study was to analyze the impact of chemotherapy on resectability and long-term survival. METHODS: From 1984 to 2005, 159 consecutive patients with non-small cell lung cancer underwent sleeve lobectomy without (n = 117) or with induction chemotherapy (n = 42). Indications for chemotherapy were N2 lymph node involvement (n = 15), T3 or T4 tumor invasion with doubtful resectability (n = 13), need for tumor size reduction (n = 8), lung function precluding pneumonectomy (n = 4), and brain metastasis (n = 2). None of the patients received induction radiation therapy. We studied tumor characteristics and immediate and long-term results in both groups. RESULTS: Clinical stage III was predominant in the induction chemotherapy group whereas stage II was predominant in the surgery-only group. Complication rates in the induction chemotherapy group and in the surgery-only group were 23.8% and 24.7%, respectively. We observed a greater rate of 1-month-delay smoking cessation before surgery in the induction chemotherapy group (40% versus 22%). The 5-year survival rates were 65.4% in the surgery-only group and 73.4% in the induction chemotherapy group (p = 0.5). The tumor size in the induction chemotherapy group was lower (17.5 versus 30.6 mm; p = 0.01), which reflected the positive impact of chemotherapy on sleeve resection feasibility. CONCLUSIONS: Induction chemotherapy before sleeve lobectomy achieves good long-term results. Tumor reduction and limited resection feasibility seemed to be increased, which justify further prospective trials. |
| | |
Authors:
|
Patrick Bagan; Pascal Berna; Emmanuel Brian; Flora Crockett; Fran??oise Le Pimpec-Barthes; Antoine Dujon; Marc Riquet |
Related Documents
:
|
21296795 - Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carci... 18586485 - Analysis of sternotomy as treatment option for the resection of bilateral pulmonary met... 7818415 - Oesophageal cancer: outcome of modern surgical management. 21270615 - Clinicopathologic implications of the epidermal growth factor receptor, cyclooxygenase ... 1998475 - Prognostic factors in primary retroperitoneal soft-tissue sarcomas. 22498745 - Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consol... |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: The Annals of thoracic surgery Volume: 88 ISSN: 1552-6259 ISO Abbreviation: Ann. Thorac. Surg. Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-11-25 Completed Date: 2010-01-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 15030100R Medline TA: Ann Thorac Surg Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1732-5 Citation Subset: AIM; IM |
Affiliation:
|
Department of Thoracic Surgery, Georges Pompidou European Hospital, Paris University, Paris, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
therapeutic use* Bronchoscopy Female Follow-Up Studies Humans Lung Neoplasms / diagnosis, drug therapy*, surgery Male Middle Aged Neoplasm Staging Pneumonectomy / methods* Preoperative Care / methods* Retrospective Studies Time Factors Tomography, X-Ray Computed Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
| Comments/Corrections | |
Comment In:
|
Ann Thorac Surg. 2009 Dec;88(6):1736
[PMID:
19932226
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Richard Anderson: cardiothoracic surgeon personified.
Next Document: Risk factors for early mortality and morbidity after pneumonectomy: a reappraisal.